Enterprise Value (EV): $11.30B
The enterprise value (EV) is $11.30B as of Saturday, June 27, 2026.
TECH Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$11.30B
TECH Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | $11.30B |
| Insulet Corp. (PODD)vs › | $10.96B | $11.43B |
| Baxter International Inc. (BAX)vs › | $11.38B | $19.05B |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | $10.43B |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | $38.64B |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | $13.06B |
| Tempus AI, Inc. (TEM)vs › | $9.80B | $10.59B |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | $13.29B |
| Revvity, Inc. (RVTY)vs › | $12.61B | $15.10B |
| Align Technology, Inc. (ALGN)vs › | $12.78B | $11.84B |
Enterprise Value Calculation
Market Cap
$11.12B
Total Debt
$346.00M
Cash
$162.19M
Enterprise Value
$11.30B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Bio-Techne Corporation (TECH)?
- The enterprise value (EV) for TECH stock is $11.30B.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman